


**ABSTRACT**

Pyrimidines of formula (1) are described

5



wherein Ar is an optionally substituted aromatic or heteroaromatic group;

R<sup>1</sup> is a hydrogen atom or a straight or branched chain alkyl group;

R<sup>2</sup> is a -X<sup>1</sup>-R<sup>3</sup> group where X<sup>1</sup> is a direct bond or a linker atom or group, and

10 R<sup>3</sup> is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group;  
and the salts, solvates, hydrates and N-oxides thereof.

The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and

15 are of use in the prophylaxis and treatment of disease states associated with angiogenesis.

20